Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Hynes

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Bioorganic & Medicinal Chemistry Letters|May 28, 2013
The discovery of BMS-457, a potent and selective CCR1 antagonistDaniel S Gardner, Joseph B Santella, John V Duncia, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 2017
Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitorsJohn Hynes, Hong Wu, James Kempson, et al.
Journal of Medicinal Chemistry|September 12, 2015
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase InhibitorChunjian Liu, James Lin, John Hynes, et al.
Journal of Medicinal Chemistry|December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitorsJohn Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitorsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry|August 8, 2014
Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritisJoseph B Santella, Daniel S Gardner, John V Duncia, et al.
Journal of Medicinal Chemistry|September 1, 2010
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseasesChunjian Liu, James Lin, Stephen T Wrobleski, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2020
Tricyclic sulfones as potent, selective and efficacious RORγt inverse agonists - Exploring C6 and C8 SAR using late-stage functionalizationQing Shi, Zili Xiao, Michael G Yang, et al.
Journal of Medicinal Chemistry|December 2, 2020
Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design ApproachesHai-Yun Xiao, Ning Li, James J-W Duan, et al.
Journal of Medicinal Chemistry|November 30, 2004
The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinaseKaterina Leftheris, Gulzar Ahmed, Ran Chan, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|May 28, 2013
The discovery of BMS-457, a potent and selective CCR1 antagonistDaniel S Gardner, Joseph B Santella, John V Duncia, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 2017
Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitorsJohn Hynes, Hong Wu, James Kempson, et al.
Journal of Medicinal Chemistry|September 12, 2015
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase InhibitorChunjian Liu, James Lin, John Hynes, et al.
Journal of Medicinal Chemistry|December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitorsJohn Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitorsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry|August 8, 2014
Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritisJoseph B Santella, Daniel S Gardner, John V Duncia, et al.
Journal of Medicinal Chemistry|September 1, 2010
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseasesChunjian Liu, James Lin, Stephen T Wrobleski, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2020
Tricyclic sulfones as potent, selective and efficacious RORγt inverse agonists - Exploring C6 and C8 SAR using late-stage functionalizationQing Shi, Zili Xiao, Michael G Yang, et al.
Journal of Medicinal Chemistry|December 2, 2020
Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design ApproachesHai-Yun Xiao, Ning Li, James J-W Duan, et al.
Journal of Medicinal Chemistry|November 30, 2004
The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinaseKaterina Leftheris, Gulzar Ahmed, Ran Chan, et al.
Pageof 6